YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus |
Han, Taedong
(Department of Applied Chemistry and Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University)
Lee, Byoung Moon (Yuhan R&D Institute) Park, Yoo Hoi (Yuhan R&D Institute) Lee, Dong Hoon (Yuhan R&D Institute) Choi, Hyun Ho (Yuhan R&D Institute) Lee, Taehoon (Department of Applied Chemistry and Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University) Kim, Hakwon (Department of Applied Chemistry and Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University) |
1 | DeFronzo, R. A. (2009) Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773-795. |
2 | Drucker, D. J. (1998) Glucagon-like peptide. Diabetes 47, 159-169. |
3 | Han, T. D., Jung, E. H., Yi, C. H., Lee, B. M., Park, Y. H., Lee, D. H., Kang, J. H., Yang, N. Y., Kim, D. H., Hyun, K. H., Park, K. J., Lee, C. H. and Nam, S. H. (2014) Novel triazolone derivatives or salts thereof and pharmaceutical composition comprising the same. PCT International applications WO2014175621 A1. 2014 Apr 22. |
4 | Hothersall, J. D., Bussey, C. E., Brown, A. J., Scott, J. S., Dale, I. and Rawlins, P. (2015) Sustained wash-resistant receptor activation response of GPR119 agonist. Eur. J. Pharmacol. 762, 430-442. DOI |
5 | Jones, R. M., Leonard, J. N., Buzard, D. J. and Lehmann, J. (2009) GPR119 agonists for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 19, 1339-1359. DOI |
6 | Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vaccaro, N., Xi, L., Polidori, D. C., Vets, E., Sarich, T. C. and Stein, P. P. (2011) Pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-38431055, a novel GPR119 receptor agonist and potential antidiabetes agent, in healthy male subjects. Clin. Pharmacol. Ther. 90, 685-692. |
7 | Katz, L. B., Gambale, J. J., Rothenberg, P. L., Vanapalli, S. R., Vaccaro, N., Xi, L., Sarich, T. C. and Stein, P. P. (2012) Effects of JNJ-38431055, a novel GPR119 receptor agonist, in randomized, double-blind, placebo-controlled studies in subjects with type 2 diabetes. Diabetes Obes. Metab. 14, 709-716. DOI |
8 | Koro, C. E., Bowlin, S. J., Bourgeois, N. and Fedder, D. O. (2004) Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes. Diabetes Care 27, 17-20. DOI |
9 | Blad, C. C., Tang, C. and Offermanns, S. (2012) G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11, 603-619. DOI |
10 | Bailey, C. J. (2008) Metformin: effects on micro and macrovascular complications in type 2 diabetes. Cardiovasc. Drugs Ther. 22, 215-224. DOI |
11 | Chu, Z. L., Jones, R. M., He, H., Carroll, C., Gutierrez, V., Lucman, A., Moloney, M., Gao, H., Mondala, H., Bagnol, D., Unett, D., Liang, Y., Demarest, K., Semple, G., Behan, D. P. and Leonard, J. (2007) A role for beta-cell-expressed G protein-coupled receptor 119 in glycemic control by enhancing glucose-dependent insulin release. Endocrinology 148, 2601-2609. DOI |
12 | Morales, J. (2011) The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors. Postgrad. Med. 123, 189-201. DOI |
13 | Cornall, L. M., Hryciw, D. H., Mathai, M. L. and McAinch, A. J. (2015) Direct activation of the proposed anti-diabetic receptor, GPR119 in cardiomyoblasts decreases markers of muscle metabolic activity. Mol. Cell Endocrinol. 402, 72-85. |
14 | Cusi, K., Consoli, A. and DeFronzo, R. A. (1996) Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81, 4059-4067. |
15 | DeFronzo, R. A., Bonadonna, R. C. and Ferrannini, E. (1999) Pathogenesis of NIDDM. A balanced overview. Diabetes Care. 15, 318-368. |
16 | Lauffer, L., Iakoubov, R., Brubaker, P. L. (2008) GPR119: "double-dipping" for better glycemic control. Endocrinology 149, 2035-2037. DOI |
17 | Lauffer, L. M., Iakoubov, R., Brubaker, P. L. (2009) GPR119 is essential for oleoylethanolamide-induced glucagon-like peptide-1 secretion from the intestinal enteroendocrine L-cell. Diabetes 58, 1058-1066. DOI |
18 | Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S. and Young, L. H. and Kahn, R. (2003) Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108, 2941-2948. |
19 | Nunez, D. J., Bush, M. A., Collins, D. A., McMullen, S. L., Gillmor, D., Apseloff, G., Atiee, G., Corsino, L., Morrow, L. and Feldman, P. L. (2014) Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies. PLoS ONE 9, e92494. DOI |
20 | Nilsson, C., Raun, K., Yan, F. F., Larsen, M. O. and Tang-Christensen, M. (2012) Laboratory animals as surrogate models of human obesity. Acta Pharmacol. Sin. 33, 173-181. DOI |
21 | Overton, H. A., Babbs, A. J., Doel, S. M., Fyfe, M. C., Gardner, L. S., Griffin, G., Jackson, H. C., Procter, M. J., Rasamison, C. M., Tang-Christensen, M., Widdowson, P. S., Williams, G. M. and Reynet, C. (2006) Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab. 3, 167-175. DOI |
22 | Taylor, S. I., Accili, D. and Imai, Y. (1994) Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM. Diabetes 43, 735-740. DOI |
23 | Overton, H. A., Fyfe, M. C. and Reynet, C. (2008) GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesity. Br. J. Pharmacol. 153 Suppl 1, S76-S81. |
24 | Ritter, K., Buning, C., Halland, N., Poverlein, C. and Schwink, L. (2016) G protein-coupled receptor 119 (GPR119) agonists for the treatment of diabetes: Recent progress and prevailing challenges. J. Med. Chem. 59, 3579-3592. DOI |
25 | Sakamoto, Y., Inoue, H., Kawakami, S., Miyawaki, K., Miyamoto, T., Mizuta, K. and Itakura, M. (2006) Expression and distribution of Gpr119 in the pancreatic islets of mice and rats: predominant localization in pancreatic polypeptide-secreting PP-cells. Biochem. Biophys. Res. Commun. 351, 474-480. DOI |
26 | Yip, R. G. and Wolfe, M. M. (2000) GIP biology and fat metabolism. Life Sci. 66, 91-103. |
27 | UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352, 854-865. DOI |